OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Other Events
Item 8.01. Other Events.
OWC Pharmaceutical Research Corp. (OWC) is reporting the issuance
on April 5, 2017 of the attached press release, announcing that
as a result of the promising conclusions reported in its Form 8-K
filed on March 20, 2017, the Company has received expressions of
scientific and medical interest, world-wide, for its
cannabinoid-based topical cream for treating psoriasis. OWC has
expanded the size and scope of its clinical studies and, as
previously announced, anticipates that subject to pending
regulatory approvals from applicable jurisdictions, the topical
cream should be available for use by those who suffer from
psoriasis in the near term.
Reference is made to the full text of the press release filed as
Exhibit 99.1 herewith.
Item 9.01 Financial Statements and Exhibits.
(a) The following documents are filed as exhibits to this report
on Form 8-K or incorporated by reference herein. Any document
incorporated by reference is identified by a parenthetical
reference to the SEC filing that included such document.
|
Exhibit No. |
Description |
| 99.1 | Press Release dated April 5, filed herewith. |
About OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP)
OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system. OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Recent Trading Information
OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) closed its last trading session down -0.041 at 0.969 with 2,167,280 shares trading hands.